04 Jan 2021 --- Netherlands-based Winclove Probiotics is developing Novobiome, a new platform to bring human-derived, next-generation probiotics (NGPs) to the European market.The company aims to generate €8 million (US$9.8 million) in turnover within the first five years of commercializing Novobiome.